SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (461)12/28/1997 1:49:00 AM
From: Brander  Read Replies (1) of 834
 
Bill, "When the company obfuscates the fact that these are licensed or generic drugs and instead implies that they were developed in-house, then I would question the integrity of management."

I agree with that statement, and it is a point worth pondering. Below is a link to a 10-K that gives some interesting history of Novastan (Argatroban).

sec.gov

Nevertheless, if Novastan is approved by the FDA, TXB stock price should jump significantly, as it potentialy has a large market. If TXB fudged the results of their clinical trials, and Navastan is rejected by the FDA, then the stock will almost certainly crash.

I have read some of the clinical results, and they seem sound to me.
If you have any information concerning the integrity of the reported results, I would greatly appreciate it.

I appreciate your response. You are now supplying some valid substance to your concerns.

Brad
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News